Jazz serving mirv verve: $75M-plus to Immunogen via early stage ADCs deal
By Randy Osborne
Staff Writer
Staff Writer
Immunogen Inc. has enough cash – almost – to reach the phase III readout with ADC mirvetuximab soravtansine in ovarian cancer, thanks to the option deal for earlier-stage ADCs with Jazz Pharmaceuticals plc, which paid $75 million up front.
